PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
18503633-12	2008	Treatments exerted no effect on vascular Cox-1 mRNA whereas Cox-2 mRNA was moderately reduced by aspirin and triflusal (placebo 100% +/- 9%, aspirin 70% +/- 2% and triflusal 70% +/- 2%; P < 0.05).	triflusal	109-118	cytochrome c oxidase subunit II	Oryctolagus cuniculus	60-65	
18503633-12	2008	Treatments exerted no effect on vascular Cox-1 mRNA whereas Cox-2 mRNA was moderately reduced by aspirin and triflusal (placebo 100% +/- 9%, aspirin 70% +/- 2% and triflusal 70% +/- 2%; P < 0.05).	triflusal	164-173	cytochrome c oxidase subunit II	Oryctolagus cuniculus	60-65	
18503633-13	2008	Cox-2 protein levels were slightly higher in the triflusal versus aspirin group (placebo 100% +/- 6%, aspirin 35% +/- 10% and triflusal 61% +/- 9%; P < 0.005 versus placebo).	triflusal	49-58	cytochrome c oxidase subunit II	Oryctolagus cuniculus	0-5	
18503633-13	2008	Cox-2 protein levels were slightly higher in the triflusal versus aspirin group (placebo 100% +/- 6%, aspirin 35% +/- 10% and triflusal 61% +/- 9%; P < 0.005 versus placebo).	triflusal	126-135	cytochrome c oxidase subunit II	Oryctolagus cuniculus	0-5	
18503633-15	2008	CONCLUSIONS: At a similar level of efficacy in inhibiting secondary thrombosis, triflusal seems to better preserve Cox-2 expression than aspirin and its metabolite HTB was able to protect endothelial prostacyclin production.	triflusal	80-89	cytochrome c oxidase subunit II	Oryctolagus cuniculus	115-120